Search Results
Your search for ,NOt matches 22378 pages
Showing 6851 - 6900Expert Point of View: Jason J. Luke, MD
Invited discussant of the C-144-01 study,1 Jason J. Luke, MD, Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center, University of Pittsburgh Hillman Cancer Center, Pittsburgh, noted that lifileucel is “clearly an active regimen in the post–PD-1/CTLA-4 setting and one ...
Early Adopter of Breast Conservation, Surgical Oncologist Augusto Leon, MD, Reflects on Cancer Care in Chile
In this installment of the occasional department on Global Health-Care Equity, Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Augusto Leon, MD, a surgical oncologist and Head of the Program of Cancer at Pontifical University of Chile, Santiago. Dr. Are is JL & CJ Varner...
Lifileucel After Disease Progression in Metastatic Melanoma: Durable Responses Achieved in Phase II Trial
Despite the fact that we have made significant progress in metastatic melanoma with immune checkpoint inhibitors—now the standard of care—most patients experience disease progression and are left without approved treatments. There is a need for newer treatments with clinical benefit. Lifileucel, an ...
Predicting Global Cancer Trends in 2021
Although we are just halfway through 2021, the outlook for improvements in global cancer trends looks grim. According to new estimates by the International Agency for Research on Cancer’s Global Cancer Observatory, the global cancer burden rose to 19.3 million cases and 10 million deaths in 2020...
ADAPT Trial: ‘Excellent’ Outcomes Reported With Neoadjuvant Dual HER2 Therapy in Breast Cancer
The first overall survival analysis of the WGS-ADAPT HER2+/HR– study, which evaluated neoadjuvant therapy in patients with hormone receptor–negative, HER2-positive disease, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or with the chemotherapy-free regimen of...
Sacituzumab Govitecan-hziy: Welcome Addition to Advanced Urothelial Cancer Treatments, but Time to Figure Out Sequencing and Combinations
The results of Cohort 1 of the phase II trial TROPHY-U-01 (IMMU-132-06; ClinicalTrials.gov identifier NCT03547973), published in the Journal of Clinical Oncology by Tagawa et al and reviewed in this issue of The ASCO Post, led to the recent accelerated U.S. Food and Drug Administration (FDA)...
Reducing Prostate Cancer Disparity by Bringing Care to Underserved Populations
The dire cancer incidence and mortality statistics for Black patients compared with White patients are well known. Collectively, Black individuals have the highest mortality rate and shortest survival of any racial or ethnic group in the United States for most cancers. Black men also have the...
Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer
The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...
Postoperative Mortality and Complications After Cancer Surgery in High- vs Low- or Middle-Income Countries
In a prospective cohort study reported in The Lancet, the GlobalSurg Collaborative found that 30-day mortality after surgery for colorectal and gastric cancers, but not breast cancer, was higher in low- or middle-income countries vs high-income countries.1 Among all patients, mortality rates...
Disease Risk Associated With Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes
In a study reported in TheNew England Journal of Medicine, Leila Dorling, PhD, of the Centre for Cancer Genetic Epidemiology, Departments of Public Health and Primary Care, University of Cambridge, United Kingdom, and colleagues in the international Breast Cancer Association Consortium (BCAC),...
Caryn Lerman, PhD, Elected President of the AACI
Caryn Lerman, PhD, is the new President of the Association of American Cancer Institutes (AACI). Dr. Lerman is Director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles and Associate Dean for Cancer Programs and the H. Leslie and Elaine S. Hoffman...
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
On May 20, 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the...
Enfortumab Vedotin-ejfv Granted Regular Approval in Treatment of Locally Advanced or Metastatic Urothelial Cancer
On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and...
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma
Patients with multiple myeloma had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published by Van Oekelen et al in Cancer Cell. Mount...
Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?
Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all patient age groups, especially in those younger than 50 years. These results raise fresh concerns...
BCMA-Directed CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In the phase Ib/II CARTITUDE-1 trial reported in The Lancet, Jesus G. Berdeja, MD, and colleagues found that ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy with two B-cell maturation antigen (BCMA)-targeting single-domain antibodies, produced a high rate of...
Is Chemotherapy Associated With Complications or Poorer Outcomes Among Women Undergoing Immediate Breast Reconstruction?
In a cohort study reported in JAMA Surgery, Hart et al found that treatment with either neoadjuvant or adjuvant chemotherapy was not associated with an increased risk of complications or poorer patient-reported outcomes in women undergoing mastectomy for breast cancer with immediate breast...
Parenthood Status and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors
In a Danish population-based study reported in the Journal of Clinical Oncology, Øvlisen et al found that parenthood rates in younger Hodgkin lymphoma survivors who did not experience early relapse were similar to those in the general population, but that use of assisted reproductive techniques...
Study Recommends Improvements for Cancer Care at Network Sites
New research published in JNCCN—Journal of the National Comprehensive Cancer Network assessed the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers. The study was developed to implement strategies for disseminating discoveries and...
Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer
In a study reported in The New England Journal of Medicine, Awad et al identified potential mechanisms of acquired resistance to the KRAS G12C inhibitor adagrasib in patients receiving the agent for treatment of KRAS G12C–mutant cancers. As noted by the investigators, clinical trials of the KRAS...
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
Research published by Pratt et al in Annals of Surgical Oncology showed an increase in survival rates when treatment options—surgery, chemotherapy, and radiation—are completed within 38 weeks from the time of diagnosis for patients with breast cancer. Optimal Treatment Duration The observational...
Individualized Nutritional Support for Patients With Cancer
Among 506 hospitalized patients with cancer at risk of malnutrition, individualized nutritional support reduced the risk of mortality compared to consumption of standard hospital food. The findings from a preplanned secondary analysis of the prospective, randomized, multicenter EFFORT trial,...
Addition of Pembrolizumab to Chemoradiotherapy in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
As reported in JAMA Oncology by Osama E. Rahma, MD, and colleagues, initial results of the phase II NRG-GI002 trial showed no improvement in mean neoadjuvant rectal score with the addition of pembrolizumab to chemoradiotherapy in total neoadjuvant therapy for patients with locally advanced rectal...
Oncolytic Adenovirus for Malignant Glioma: Feasibility and Safety
In a first-in-human phase I trial reported in The Lancet Oncology, Fares et al found that neural stem cell delivery of an oncolytic adenovirus (NSC-CRAd-S-pk7) was safe and feasible in patients with newly diagnosed malignant glioma, with immunologic and histopathologic findings supporting continued ...
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma
On July 6, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab, an anti–PD-1 agent, as monotherapy for patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation. This approval is based on data from the second...
Study Explores Co-occurring Mutations in HER2 and HER3
Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, according to a new study. The findings, published by Hanker et al in Cancer Cell, could explain why many patients with HER2...
Recovery of Gonadal Function With PET-Adapted Regimen for Advanced Hodgkin Lymphoma
In a prospective analysis from the phase III Lymphoma Study Association AHL2011 trial reported in the Journal of Clinical Oncology, Demeestere et al found that patients with advanced Hodgkin lymphoma receiving a positron-emission tomography (PET)-adapted regimen had a reduced risk of gonadal...
Humanized CD19-Targeted CAR T-Cell Treatment in Patients With Relapsed or Refractory B-Cell ALL
In a pilot study reported by Myers et al in the Journal of Clinical Oncology, a humanized CD19-targeted chimeric antigen receptor (CAR) T-cell product developed by the investigators (huCART19) was found to produce durable remissions and prolonged CAR T-cell persistence in CAR-naive and CAR-exposed...
Responses to Pembrolizumab and Ipilimumab After Anti–PD-1/L1 Failure in Advanced Melanoma
Despite new and effective treatments for melanoma with checkpoint inhibitors and targeted therapies, patients with metastatic melanoma who progress on frontline treatment generally do very poorly. “We really need to make sure we give these patients access to drugs that we know have some efficacy,”...
Efficiency of Virtual Care for Oncology Patients During the COVID-19 Pandemic
In a single-institution study reported in JCO Oncology Practice, Hsiehchen et al found that replacement of in-person with telehealth visits among patients with cancer initiating systemic therapy during the COVID-19 pandemic was not associated with poorer efficiency in components of oncology care or ...
Assessment of Targeted Methylation-Based Multicancer Early Detection Test in Independent Validation Cohort
In a validation study reported in Annals of Oncology, Klein et al found that a targeted methylation-based multicancer early detection (MCED) assay using cell-free DNA (cfDNA) sequencing had high specificity for cancer signal detection and high accuracy in predicting cancer signal origin across a...
Second-Line Pembrolizumab Plus Chemotherapy Regimen for Relapsed or Refractory Classic Hodgkin Lymphoma
In a phase II trial reported in the Journal of Clinical Oncology, Alison J. Moskowitz, MD, and colleagues found that second-line therapy with pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in relapsed or refractory classic Hodgkin lymphoma produced responses in all...
Expert Point of View: Rebecca A. Snyder, MD, MPH
The invited discussant of the Alliance A21501 findings, Rebecca A. Snyder, MD, MPH, Assistant Professor of Surgical Oncology at the Brody School of Medicine at East Carolina University, Greenville, described the overall survival associated with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, ...
Modified FOLFIRINOX Established as Preferred Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
In the treatment of borderline resectable pancreatic ductal adenocarcinoma, the Alliance A021501 trial established neoadjuvant treatment with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) as a new benchmark. However, it failed to show the benefit of adding...
Personalizing Treatment of Early HER2-Positive Breast Cancer
With several pivotal trials providing evidence for the escalation and de-escalation of anti-HER2 therapy in certain early breast cancer scenarios, personalized treatment is possible. How can clinicians optimize treatment by applying the studies’ findings? Debu Tripathy, MD, Professor and Chair of...
Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer
In the German phase III SUCCESS A trial reported in JAMA Oncology, Friedl et al found no differences in disease-free or overall survival with 5 vs 2 years of zoledronate treatment following adjuvant chemotherapy for early breast cancer. Study Details In the multicenter, open-label, 2 × 2 factorial...
Survey Finds COVID-19 Vaccine Hesitancy Among Many Adolescent and Young Adult Cancer Survivors
Despite recommendations from ASCO and other national organizations that cancer survivors, as well as patients on active treatment, receive the COVID-19 vaccine if they have no contraindications, a survey of adolescent and young adult cancer survivors finds many have vaccine hesitancy. According to...
Sintilimab Plus Bevacizumab Biosimilar vs Sorafenib in Unresectable or Metastatic HBV-Associated Hepatocellular Carcinoma
In a Chinese phase II/III trial (ORIENT-32) reported in The Lancet Oncology, Ren et al found that the combination of the PD-1 inhibitor sintilimab and the bevacizumab biosimilar IBI305 prolonged progression-free and overall survival vs sorafenib in previously untreated unresectable or metastatic...
Study Examines Mechanisms of Resistance in Early-Stage Breast Cancer After Endocrine Plus CDK4/6 Therapy
About 80% of breast cancer cases are hormone receptor–positive, according to the American Cancer Society. Patients with estrogen receptor–positive breast cancer generally are treated using therapy that inhibits both estrogen levels and cell-cycle activity, but about 90% of patients with metastatic...
Immunotherapy May Be Effective for Subset of Patients With Prostate Cancer
In recent years, cancer immunotherapy has been effective in treating patients with immunogenic—or “hot”—tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered a “cold” tumor, with few immune cells recognizing...
Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer: What’s Next?
Because of their well-established efficacy, inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are the standard of care in the treatment of hormone receptor–positive, HER2-negative metastatic breast cancer. The question now is this: after disease progresses on a CDK4/6 inhibitor and endocrine...
Risk Factors for Early Discontinuation of Adjuvant Endocrine Therapy for Breast Cancer
In a post hoc analysis from the phase III TAILORx trial reported in JAMA Oncology, Yanez et al identified factors that may be associated with an increased and decreased likelihood of early discontinuation of adjuvant endocrine therapy for breast cancer. Study Details The TAILORx trial, conducted...
Addition of First-Line Camrelizumab to Gemcitabine/Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma
In an interim analysis of a Chinese phase III trial (CAPTAIN-1st) reported in The Lancet Oncology, Yang et al found that the addition of camrelizumab to gemcitabine and cisplatin significantly prolonged progression-free survival in the first-line treatment of recurrent or metastatic nasopharyngeal ...
Are Patients With Primary Lung Cancer Detected by Low-Dose CT at Reduced Risk of Brain Metastases?
Patients with primary lung cancer detected using low-dose computed tomography (CT) screening may be at reduced risk for developing brain metastases after diagnosis, according to a study published in the Journal of Thoracic Oncology. The researchers, led by Summer Han, PhD, of Stanford University...
Improving Screening of Dense Breasts With Newer MRI Technologies
Women with dense breasts are increasingly being screened with magnetic resonance imaging (MRI), which is clearly the best way to detect small cancers in this population, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology at the University of...
ASCO-ACCC Piloting Project to Test Tools to Diversify Cancer Clinical Trials
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, ASCO and the Association of Community Cancer Centers (ACCC) recently announced plans to test a research site assessment tool and implicit bias training...
ASCO Releases Recommendations for Management of Salivary Gland Malignancies
Given the rarity of salivary gland malignancies—neoplasms that account for less than 1% to 5% of all head and neck cancers—limited evidence exists to support informed treatment guidance. The overall variability in the biologic behaviors of these neoplasms has further complicated clinical...
Emerging Reasons for Optimism in Lung Cancer
Despite public smoking cessation initiatives and improved methods for early detection and treatment, lung cancer persists as the leading cause of cancer death in both men and women in the United States. However, over the past decade, smoking cessation efforts, increased screening, and new...
How to Talk With Teens and Young Adults About Their End-of-Life Goals
Although death rates for adolescent and young adults (AYAs) with cancer have been dropping 0.8% a year from 2009 to 2018, cancer remains a leading disease-related cause of death among this patient population. This year, the National Cancer Institute (NCI) estimates that 88,260 AYAs, defined by the...
Better Responses to Hepatic Arterial Infusion Therapy Among Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Patients with colorectal cancer and unresectable liver metastases and KRAS wild-type disease experienced better responses to hepatic arterial infusion pump chemotherapy than did patients with KRAS mutations, a retrospective cohort study found. At a median follow-up of 14.6 months, “KRAS-positive...
